|
Phase 2, multicenter, randomized study of salvage radiation therapy +/- metformin for recurrent prostate cancer after radical prostatectomy (SAKK 08/15 – GETUG-AFU 34 PROMET trial). |
|
|
Employment - University of Miami Hospitals and Clinics |
Leadership - University of Miami Hospitals and Clinics |
|
|
Employment - Astellas Pharma; AstraZeneca; Bayer; Ferring; Ipsen; Janssen; Takeda |
Speakers' Bureau - Gerson Lehrman Group |
Research Funding - Astellas Medivation (Inst); Janssen (Inst) |
Travel, Accommodations, Expenses - Ipsen |
Other Relationship - Astellas Pharma; Janssen Oncology |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Astellas Pharma; Janssen-Cilag |
Consulting or Advisory Role - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Janssen-Cilag; MSD Oncology; Pfizer; Roche (Inst); Sanofi (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Janssen-Cilag AG |
Speakers' Bureau - Janssen-Cilag |
Research Funding - AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); Takeda (Inst) |
|
|
No Relationships to Disclose |
|
|
Research Funding - ViewRay (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
Alexandros Papachristofilou |
Honoraria - Astellas Pharma (Inst); Debiopharm Group (Inst); Janssen (Inst); Merck Serono (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bytec Medizintechnik; Dr. Sennewald Medizintechnik |
Research Funding - Oncotherm |
|
|
Consulting or Advisory Role - Janssen; Merck; Myriad Genetics; Roche |
|
|
Consulting or Advisory Role - AAA HealthCare (Inst); Amgen; Amgen (Inst); Amgen (Inst); AstraZeneca; AstraZeneca (Inst); Bayer (Inst); BMS (Inst); ESMO; German-speaking European School of Oncology (DESO); Modra Pharmaceuticals (Inst); MSD Oncology; MSD Oncology (Inst); Myriad Genetics (Inst); Novartis (Inst); Orion (Inst); Pfizer (Inst); Radiotelevisione Svizzera Italiana (RSI); Silvio Grasso Consulting (Inst); Swiss Academy of Multidisciplinary oncology (SAMO); Swiss Group for Clinical Cancer Research (SAKK); Telix Pharmaceuticals (Inst); TOLREMO (Inst); WebMD/Medscape (Inst) |
Patents, Royalties, Other Intellectual Property - Method for biomarker (WO 3752009138392 A1) |
Travel, Accommodations, Expenses - AstraZeneca |
Other Relationship - ProteoMediX |
|
|
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Janssen (Inst); Molecular Partners (Inst); MSD (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst) |
Speakers' Bureau - Advanced accelerator; Astellas Pharma; Astellas Pharma (Inst); Bayer (Inst); Janssen-Cilag; Janssen-Cilag (Inst) |
Research Funding - Janssen (Inst); Teva (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Janssen; Sanofi |
|
|
Leadership - SWAN Isotopen |
|
Consulting or Advisory Role - Roche |
Research Funding - Merck KGaA (Inst) |